Dermata Therapeutics Inc (DRMA)

$DRMA 90 DAYS STOCK PRICE FORECAST

Stock Price

About the Company

We do not have any company description for Dermata Therapeutics Inc at the moment.

Sector

Manufacturing

Industry

Medicinal and Botanical Manufacturing

Employees

2021

Exchange

NASDAQ

$M

Total Revenue

2K

Employees

$20M

Market Capitalization

-2.46

Price/Earning ratio

Similar Companies

Name Ticker Market Capitalization (USD M) Revenue (USD M) Price/Book Price/Earning Net Margin (%)
Conversion Labs Inc CVLB 108548 35213 3.74 42.66 7.33
Royalty Pharma plc RPRX 21578 2286 2.88 20.15 13.26
Organon & Co. OGN 7323 7878 -4.52 4.82 19.26
Arvinas Inc ARVN 3963 23 4.93 -19.95 -794.96
Tilray Inc TLRY 2976 564 0.99 -7.48 -66.49
Usana Health Sciences Inc USNA 2079 1230 4.83 15.14 11.04
ATAI Life Sciences N.V. ATAI 1782 20 3.94 -10.71 -821.63
Cronos Group Inc CRON 1527 57 0.96 -10.58 -258.59
DICE Therapeutics Inc DICE 1211 1 3.72 -30.64 None
NRX Pharmaceuticals Inc NRXP 1170 2321 0.45 5.05 9.91
Intersect ENT Inc XENT 893 104 56.35 -10.09 -85.02
Ventyx Biosciences Inc VTYX 877 -10.72 -10.48 None
Phibro Animal Health Corp. PAHC 827 853 3.50 16.81 5.70
Edgewise Therapeutics Inc EWTX 793 2.79 -21.86 None
Phathom Pharmaceuticals Inc PHAT 673 5.72 -4.13 None
Theseus Pharmaceuticals Inc THRX 567 -12.12 -26.25 None
Cyteir Therapeutics Inc CYT 548 2.80 -15.36 None
Rani Therapeutics Holdings Inc RANI 514 3 9.84 -25.43 -678.00
Urovant Sciences Ltd UROV 503 -3.65 -3.08 None
Pliant Therapeutics Inc PLRX 475 10 2.16 -5.04 -914.12
Fulcrum Therapeutics Inc FULC 472 18 2.59 -6.30 -409.62
Ikena Oncology Inc IKNA 465 11 2.28 -7.38 -581.21
Provention Bio Inc PRVB 399 1 3.08 -3.27 None
Rain Therapeutics Inc RAIN 350 413 2.42 -9.15 123.20
Chromadex Corp CDXC 299 65 8.71 -10.53 -42.83
Adicet Bio Inc ACET 279 10 1.52 4.84 -570.14
Verrica Pharmaceuticals Inc VRCA 241 12 6.26 -6.30 -320.98
Evolus Inc EOLS 239 86 3.10 -1.40 -162.78
Milestone Pharmaceuticals Inc MIST 231 15 1.32 -7.52 -230.90
Aquestive Therapeutics Inc AQST 194 47 -3.59 -3.11 -132.11
Terns Pharmaceuticals Inc TERN 193 1.13 -5.54 None
Cognition Therapeutics Inc CGTX 185 -2.24 -15.75 None
Anebulo Pharmaceuticals Inc ANEB 149 7.62 -3.81 None
Citius Pharmaceuticals Inc CTXR 134 1.68 -5.85 None
Opiant Pharmaceuticals Inc OPNT 134 44 3.01 107.00 3.58
Kaleido Biosciences Inc KLDO 132 1 4.80 -1.48 None
Xeris Biopharma Holdings Inc XERS 124 35 -100.00 -1.36 -265.78
scPharmaceuticals Inc SCPH 115 119 1.85 -4.10 -27.05
Kala Pharmaceuticals Inc KALA 107 12 1.84 -0.85 None
LifeMD Inc LFMD 107 78 -6.93 -0.96 -95.77
Aerpio Pharmaceuticals Inc ARPO 99 15 2.98 -5.24 -28.77
Eyenovia Inc EYEN 94 6 24.00 -4.74 -332.81
Eton Pharmaceuticals Inc ETON 92 16 5.75 -8.36 -67.52
Natural Alternatives Internati NAII 78 177 0.97 6.99 6.64
Osmotica Pharmaceuticals Plc OSMT 76 166 1.83 -0.75 -60.32
Mannatech Inc MTEX 70 159 2.68 9.09 5.00
Odonate Therapeutics Inc ODT 58 0.83 -0.57 None
India Globalization Capital In IGC 58 0 2.05 -5.00 -981.18
Context Therapeutics Inc CNTX 57 -2.81 -8.19 None
Assertio Holdings Inc ASRT 55 108 0.65 -1.32 -28.04
Shineco Inc SISI 55 3 2.23 -1.07 None
VYNE Therapeutics Inc VYNE 46 17 0.85 -0.83 -507.13
Shineco Inc TYHT 44 3 2.17 -1.55 -159.60
Reviva Pharmaceuticals Holding RVPH 39 1.52 -4.50 None
Acasti Pharma Inc ACST 29 0 0.47 -2.16 -611.47
Bio-Path Holdings Inc BPTH 25 0 1.02 -2.73 18.96
Nabriva Therapeutics Plc NBRV 23 20 0.63 -0.37 -266.57
Baudax Bio Inc BXRX 21 1 -1.35 -0.45 9.10
Cyanotech Corp. CYAN 21 35 1.15 10.12 6.09
Lexaria Bioscience Corp LEXX 20 1 2.76 -5.10 -445.15
Dermata Therapeutics Inc DRMA 20 0.45 -2.46 None
Trevi Therapeutics Inc TRVI 19 2.16 -0.54 None
Hoth Therapeutics Inc HOTH 16 1.45 -1.50 None
Timber Pharmaceuticals Inc TMBR 13 0 11.00 3.07 -527.55
Sonoma Pharmaceuticals Inc. SNOA 9 17 3.02 -1.72 -31.96

Dermata Therapeutics Inc Shares Close the Week 40.7% Lower - Weekly Wrap

6d ago, source: Nasdaq

Dermata Therapeutics Inc shares closed this week 40.7% lower than it did at the end of last week. The stock is currently down ...

Dermata Therapeutics Inc (DRMA)

3d ago, source: Investing.com

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and ...

Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions

14d ago, source: Middle East North Africa Financial Network

SAN DIEGO, CA / ACCESSWIRE / November 19, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA), a clinical-stage biotechnology company focused on the treatment of medical ...

Dermata Therapeutics Shares Drop 28% After Friday Data

10d ago, source: MarketWatch

Dermata Therapeutics Inc. shares were down 28% to $2.38 one session after the company said it saw positive efficacy and safety data from its Phase 1b proof of concept study evaluating a single ...

Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions

14d ago, source: Yahoo Finance

2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA), a clinical-stage biotechnology company focused on the treatment of medical and aesthetic skin conditions, today ...

Dermata Therapeutics, Inc. (DRMA)

7d ago, source: TheStreet.com

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided ...

Dermata Therapeutics: Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions

14d ago, source: Finanznachrichten

To access the replay, dial (877) 481-4010 or (919) 882-2331 and reference conference ID: 43543. Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focusing on the treatment of ...

Dermata Therapeutics Inc DRMA

14d ago, source: Morningstar%2c Inc.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Your Portfolio